Hostname: page-component-586b7cd67f-tf8b9 Total loading time: 0 Render date: 2024-11-28T04:31:26.798Z Has data issue: false hasContentIssue false
  • English
  • Français

The Treatment of a Chronic Organic Mental Disorder with Dextromethorphan in a Man with Severe Mental Retardation

Published online by Cambridge University Press:  02 January 2018

Leisa Welch  and
Robert Sovner
Leisa Welch
Affiliation:
Craig D.D.S.O., Geneseo, New York
Robert Sovner*
Affiliation:
Harvard Community Health Plan, Medford Center, Mental Health Department, 26 City Hall Mall, Medford, MA02155, USA
*
∗Correspondence
Get access Rights & Permissions [Opens in a new window]

Abstract

Response to dextromethorphan (15 mg b.i.d.), an antitussive agent not usually considered to have psychotropic properties, was seen in a 25–year-old man with severe developmental disabilities, congenital rubella, and an organic mental disorder. Dextromethorphan affects CNS serotonergic systems, and this was the probable therapeutic mechanism. This and other published cases suggest the existence of a distinct organic mental syndrome in developmentally disabled persons which responds to drugs that increase indoleaminergic activity.

Type
Brief Reports
Information
The British Journal of Psychiatry , Volume 161 , Issue 1 , July 1992 , pp. 118 - 120
Copyright
Copyright © 1992 The Royal College of Psychiatrists 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Carpenter, C. L., Marks, S. S., Watson, D. L., et al (1988) Dextromethorphan and dextrorphan as calcium channel antagonists. Brain Research, 439, 372–375.CrossRefGoogle ScholarPubMed
Kastner, T., Friedman, D. L., Plaummer, A. T., et al (1990) Valproic acid for the treatment of children with mental retardation and mood symptomatology. Pediatrics, 86, 467–472.CrossRefGoogle ScholarPubMed
Markowitz, P. I. (1990) Fluoxetine treatment of self-injurious behavior in mentally retarded patients. Journal of Clinical Psychopharmacology, 10, 299–300.Google ScholarPubMed
Pollack, M. H., Rosenbaum, J. F. & Hyman, S. E. (1987) Calcium channel blockers in psychiatry. Psychosomatics, 28, 356–360.CrossRefGoogle ScholarPubMed
Reid, A. H., Ballinger, B. R. & Heather, B. B. (1978) Behavioural syndromes identified by cluster analysis in a sample of 100 severely and profoundly retarded adults. Psychological Medicine, 8, 399–412.CrossRefGoogle Scholar
Reid, A. H., Ballinger, B. R., Heather, B. B., et al (1984) The natural history of behavioural symptoms among severely and profoundly mentally retarded patients. British Journal of Psychiatry, 145, 289–293.CrossRefGoogle ScholarPubMed
Sinclair, J. G. (1973) Dextromethorphan-monoamine oxidase inhibitor interaction in rabbits. Journal of Pharmacy and Pharmacology, 25, 803–808.CrossRefGoogle ScholarPubMed
Sovner, R. (1988) Behavioral psychopharmacology: a new psychiatric subspecialty. In Mental Retardation and Mental Health: Classification, Diagnosis, Treatment, Services (eds Stark, J., Menolascino, F. J., Albarielli, M., et al). New York: Springer Verlag Google Scholar
Sovner, R. & Hurley, A. D. (1981) The management of chronic behavior disorders in mentally retarded adults with lithium carbonate. Journal of Nervous and Mental Disease, 169, 191–195.CrossRefGoogle ScholarPubMed
Sovner, R. & Wolfe, J. (1988) Interaction between dextromethorphan and monoamine oxidase inhibitor therapy with isocarboxazid. New England Journal of Medicine, 319, 1671.Google ScholarPubMed
Submit a response

eLetters

No eLetters have been published for this article.